New hope for injured newborn brains: common drug tested in groundbreaking combo therapy
NCT ID NCT06810284
Summary
This study aims to find the right dose of the drug sildenafil (often used for lung pressure) when given alongside standard cooling therapy to newborns with brain injury from oxygen deprivation at birth. It will enroll 24 full-term babies to measure how their bodies process the drug. The goal is to prepare for a larger trial to see if this combination improves survival without brain damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC ISCHEMIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre
Paris, 75005, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.